Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer’s Dementia
/
DateJan 12 2024
FDA’s De Novo approval of BrainSee represents a major advancement in Alzheimer’s diagnostics. Utilizing cutting-edge image processing and medical AI, BrainSee establishes a new standard... Read More →